With the UK Food Standards Agency (FSA) setting 31 March 2021 as the deadline for firms to have validated novel foods application for its CBD products, how are firms responding to this challenge especially in the current climate?
A glutathione-boosting supplement that debuted on the market recently to some fanfare has run afoul of the National Advertising Division’s COVID-19 claims monitoring program. The company, called INID Research Lab LLC, has agreed to discontinue a social...
A recent warning letter reiterates the importance of collecting adverse event reports in order to demonstrate full compliance with federal laws governing the manufacture and sale of dietary supplements.
The US Food and Drug Administration says it will move actively to prevent the worldwide trade in dietary ingredients, food ingredients and whole foods from being restricted because of misplaced coronavirus infection concerns.
UFC fighter Lyman Good claims his multi-vitamin was adulterated with an illegal steroid, causing him to fail a drug test, but according to a judge, he failed to make his case.
A contract manufacturer has received a warning letter for manufacturing products containing the stimulant DMHA, which was the subject of a concerted FDA enforcement action in 2019.
Ahead of the UK Food Standards Agency’s 31 March 2021 deadline for CBD products to have a validated novel foods application, the Association for the Cannabinoid Industry (ACI), which works to create a safe, legal and well-regulated CBD market in the UK,...
In light of the ongoing uncertainty around the COVID-19 public health crisis, the IPA World Congress + Probiota Americas 2020 has been canceled, but will return June 16-18, 2021 in Washington, D.C.
With the regulatory path forward for hemp-derived CBD in foods and supplements no clearer a year after the FDA’s May 2019 public meeting, trade association The Council for Responsible Nutrition (CRN) has filed a citizen’s petition urging the FDA to regulate...
A US Food and Drug Administration study reveals that a number of the products it tested labeled as ‘bitter orange’ did not meet label claim for synephrine content and more than 10% contained undeclared synthetic ingredients.
A group of hemp/CBD purveyors have teamed up with a clinical research firm to conduct a large scale study to provide the safety data that the US Food and Drug Administration says it lacks.
As Americans begin to emerge from quarantine and many cities begin the process of getting back to ‘normal,’ the FTC continues to keep an eye on companies making unsupported coronavirus claims.
The prevalence of virus-treatment claims in the marketplace has made for both heightened enforcement from federal regulators and calls for even more action from an advocacy group regarding products sold on Amazon.
A recent warning letter to a Colorado dietary supplement formulator has put front and center FDA’s determination that CBD should not be a constituent of dietary supplements.
